Liqing Yu

Dr. Liqing Yu

School of Medicine, University of Maryland, Baltimore, MD 21201, USA
orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2017 in Cell Metabolism
Verified
Journal Article
Closed access
HSHyunsu Shin
Hyunsu Shin
YMYinyan Ma
Yinyan Ma
TCTatyana Chanturiya
Tatyana Chanturiya
QCQiang Cao
Qiang Cao
YWYoulin Wang
Youlin Wang
Liqing YuLiqing Yu
Liqing Yu

9 February 2018 in Nature Communications
Verified
Journal Article
Open access
PDF file
JGJun Guo
Jun Guo
WFWeiwei Fang
Weiwei Fang
LSLibo Sun
Libo Sun
YLYonggang Lu
Yonggang Lu
LDLin Dou
Lin Dou
JLJian Li
Jian Li
Ultraconserved (uc) RNAs, a class of long non-coding RNAs (lncRNAs), are conserved across humans, mice, and rats, but the physiological significance and pathological role of ucRNAs is largely unknown. Here we show that uc.372 is upregulated in the livers of db/db mice, HFD-fed mice, and NAFLD patients. Gain-of-function and loss-of-function studies indicate that uc.372 drives hepatic lipid accumulation in mice by promoting lipogenesis. We further demonstrate that uc.372 binds to pri-miR-195/pri-miR-4668 and suppresses maturation of miR-195/miR-4668 to regulate expression of genes related to lipid synthesis and uptake, including ACC, FAS, SCD1, and CD36. Finally, we identify that uc.372 is located downstream of the insulinoma-associated 2 (INSM2) gene that is transcriptionally activated by upstream transcription factor 1 (USF1). Our findings reveal a novel mechanism by which uc.372 drives hepatic steatosis through inhibition of miR-195/miR-4668 maturation to relieve miR-195/miR-4668-mediated suppression of functional target gene expression.

6 June 2023 in Advanced Science
Verified
Journal Article
Open access
SWShirong Wang
Shirong Wang
LZLin Zha
Lin Zha
XCXin Cui
Xin Cui
YYYu‐Te Yeh
Yu‐Te Yeh
RLRuochuan Liu
Ruochuan Liu
HSHang Shi
Hang Shi
While extensive investigations have been devoted to the study of genetic pathways related to fatty liver diseases, much less is known about epigenetic mechanisms underlying these disorders. DNA methylation is an epigenetic link between environmental factors (e.g., diets) and complex diseases (e.g., non‐alcoholic fatty liver disease). Here, it is aimed to study the role of DNA methylation in the regulation of hepatic lipid metabolism. A dynamic change in the DNA methylome in the liver of high‐fat diet (HFD)‐fed mice is discovered, including a marked increase in DNA methylation at the promoter of Beta‐klotho (Klb), a co‐receptor for the biological functions of fibroblast growth factor (FGF)15/19 and FGF21. DNA methyltransferases (DNMT) 1 and 3A mediate HFD‐induced methylation at the Klb promoter. Notably, HFD enhances DNMT1 protein stability via a ubiquitination‐mediated mechanism. Liver‐specific deletion of Dnmt1 or 3a increases Klb expression and ameliorates HFD‐induced hepatic steatosis. Single‐nucleus RNA sequencing analysis reveals pathways involved in fatty acid oxidation in Dnmt1‐deficient hepatocytes. Targeted demethylation at the Klb promoter increases Klb expression and fatty acid oxidation, resulting in decreased hepatic lipid accumulation. Up‐regulation of methyltransferases by HFD may induce hypermethylation of the Klb promoter and subsequent down‐regulation of Klb expression, resulting in the development of hepatic steatosis.

17 April 2023 in Hepatology
Verified
Journal Article
Closed access
MMMallika Mathur
Mallika Mathur
YYYu‐Te Yeh
Yu‐Te Yeh
RARakesh K. Arya
Rakesh K. Arya
LJLong Jiang
Long Jiang
MPMajid Pornour
Majid Pornour
Liqing YuLiqing Yu
Liqing Yu

30 March 2021 in Pharmaceutical Research
Verified
Journal Article
Closed access
PDF file
YCYoungshim Choi
Youngshim Choi
Liqing YuLiqing Yu
Liqing Yu

19 July 2022 in Journal of Biological Chemistry
Verified
Journal Article
Open access
JPJinghua Peng
Jinghua Peng
CQCaolitao Qin
Caolitao Qin
BRBalamurugan Ramatchandirin
Balamurugan Ramatchandirin
APAlexia Pearah
Alexia Pearah
SGShaodong Guo
Shaodong Guo
Ling HeLing He
Ling He
Knockout of the transcription factor X-box binding protein (XBP1) is known to decrease liver glucose production and lipogenesis. However, whether insulin can regulate gluconeogenesis and lipogenesis through XBP1 and how insulin activates the inositol-requiring enzyme-XBP1 ER stress pathway remains unexplored. Here, we report that in the fed state, insulin-activated kinase AKT directly phosphorylates inositol-requiring enzyme 1 at S724, which in turn mediates the splicing of XBP1u mRNA, thus favoring the generation of the spliced form, XBP1s, in the liver of mice. Subsequently, XBP1s stimulate the expression of lipogenic genes and upregulates liver lipogenesis as previously reported. Intriguingly, we find that fasting leads to an increase in XBP1u along with a drastic decrease in XBP1s in the liver of mice, and XBP1u, not XBP1s, significantly increases PKA-stimulated CRE reporter activity in cultured hepatocytes. Furthermore, we demonstrate that overexpression of XBP1u significantly increases cAMP-stimulated expression of rate-limiting gluconeogenic genes, G6pc and Pck1, and glucose production in primary hepatocytes. Reexpression of XBP1u in the liver of mice with XBP1 depletion significantly increases fasting blood glucose levels and gluconeogenic gene expression. These data support an important role of XBP1u in upregulating gluconeogenesis in the fasted state. Taken together, we reveal that insulin signaling via AKT controls the expression of XBP1 isoforms and that XBP1u and XBP1s function in different nutritional states to regulate liver gluconeogenesis and lipogenesis, respectively.